Recently, InfiMotion announced the completion of hundreds of millions of yuan in Series A funding. The round was led by the National Adjustment Fund, with participation from Wuxi New Energy Industry Fund, Huiheng Industry, Huishan Financial Services, and
Today, Affection Animal Pharmaceuticals successfully completed a Series C funding round worth hundreds of millions of yuan. This equity financing was co-led by Yuanxi Haihe Fund and Songqing Shenhui Jiarui Private Investment Fund, with Guohai Innovation C
On January 8, 2024, Rokid officially signed the "Lingban Smart Investment Cooperation Agreement" with the Hefei Municipal Government. The two parties will collaborate on the development of the metaverse industry and engage in deep cooperation. Simultaneou
In recent days, leading domestic automotive recycling company Yuan Planet announced the successful completion of B1 and B2 funding rounds, raising millions of dollars. Gobi Partners GBA, Joy Capital, NIO Capital, and other institutions jointly participate
Beijing Honest Technology Co., Ltd., which focuses on X-ray acquisition and AI identification technology, Ltd. announced the completion of hundreds of millions of yuan in Series B financing. The round was led by China Venture Capital, Minmetals Innovative Investment, GuoTai JunAn ZhengYu investment and See Fund. CEC Capital acted as Honest's exclusive financial advisor on the transaction.
Nantong Jinyu BOSIN Intelligent Technology Co., Ltd., ("BOSIN" or the "Company"), a leader in China's aerial robotics automation systems industry, recently closed an A+ financing round, raising tens of millions in RMB. Central Huijin Capital led the round
Hangzhou Wanxiang Cultural Technology Co., Ltd. (" WanXiang Tech " or “Company”), a frontrunner in China's virtual content domain, successfully closed an A2 financing round worth tens of millions of RMB. In this funding round, existing shareholder Porsche Ventures increased its investment, and several strategic investment institutions also participated. CEC Capital acted as the exclusive financial advisor for Wanxiang Tech in this transaction.
Qingdao PHAGEPHARM Biotechnology Co., Ltd. ("PHAGEPHARM" or “Company”), a leading domestic provider of phage-resistant comprehensive solutions, completed a Series B financing round of nearly RMB 100 million. This financing was led by Cenova Capital, with participation from Morningside Ventures and two existing shareholders. CEC Capital served as exclusive financial advisor for this transaction.